Morgan Stanley analyst Sarita Kapila maintained a Buy rating on AstraZeneca today and set a price target of p15,500.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sarita Kapila’s rating is based on AstraZeneca’s strong position within the pharmaceutical sector, which is expected to experience significant growth. The company is highlighted as a top pick due to its sector-leading earnings growth and a promising pipeline that suggests potential for further earnings upside.
Additionally, the broader sector fundamentals appear robust, with major overhangs such as tariffs and US pricing risks largely resolved. This creates a favorable environment for AstraZeneca to capitalize on growth opportunities, particularly in areas like obesity, breast cancer, and ATTR-CM, which are expected to be key themes shaping the equity story into 2026.
Kapila covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, UCB SA, and AstraZeneca. According to TipRanks, Kapila has an average return of -1.6% and a 52.38% success rate on recommended stocks.
In another report released on December 1, Jefferies also maintained a Buy rating on the stock with a £150.00 price target.